Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer

Figure 6 E-cadherin and vimentin expression in Panc-1 and Capan-1 cells. A: Immunocytochemistry for KL-6/MUC1 and E-cadherin in: Panc-1 or Capan-1 cells pretreated with DMEM medium without drugs (a, d) or supplemented with tunicamycin (b, e) or BAG (c, f) for 48 h. (DAPI, nuclear stain, 800 × magnification), and fluorescence staining quantification(g, h); B: Western blotting and band intensity for E-cadherin and vimentin expression in Panc-1 (a, b, c) and Capan-1 (d, e, f) cells; control (a, d), 48 h treatment with 2.0 mg% tunicamycin (b, e), 48 h treatment with 5.0 mmol/L benzyl-N-acetyl-α-galactosaminide (c, f); ^aP < 0.05 vs control.